Cell Thera. +19% - 500 Beiträge pro Seite
eröffnet am 27.09.00 17:22:28 von
neuester Beitrag 27.09.00 18:56:46 von
neuester Beitrag 27.09.00 18:56:46 von
Beiträge: 3
ID: 254.467
ID: 254.467
Aufrufe heute: 0
Gesamt: 415
Gesamt: 415
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 11 Minuten | 4398 | |
vor 14 Minuten | 1882 | |
vor 19 Minuten | 1754 | |
vor 26 Minuten | 1109 | |
vor 57 Minuten | 849 | |
vor 12 Minuten | 581 | |
vor 1 Stunde | 461 | |
vor 37 Minuten | 451 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.212,17 | +0,28 | 228 | |||
2. | 2. | 152,02 | +12,36 | 175 | |||
3. | 3. | 0,1960 | +2,62 | 62 | |||
4. | 4. | 2.321,48 | -0,02 | 56 | |||
5. | 8. | 10,010 | -31,01 | 55 | |||
6. | 5. | 0,0313 | +95,63 | 49 | |||
7. | 6. | 43,50 | -0,91 | 45 | |||
8. | 7. | 4,7020 | -1,01 | 44 |
Cell hat krätig zugelegt. Ich vermute die Zulassung für das Blutkrebsmittel von der FDA ist erteilt worden.
So isses - und der Weg nach oben ist frei.
Siehe: http://www.biospace.com/b2/news_company.cfm?CompanyID=1912
Siehe: http://www.biospace.com/b2/news_company.cfm?CompanyID=1912
schon + 24%.
www.BioWorld.com:
Cell Therapeutics Gets FDA Approval For Leukemia Drug
By Matthew Willett
Staff Writer
Published on September 27, 2000
Cell Therapeutics Inc. said its apoptosis-inducing leukemia therapeutic Trisenox (arsenic trioxide)
received FDA approval for treatment of acute promyelocytic leukemia.
The company plans to market the drug independently, using a 16-person sales force.
Trading in the company`s stock (NASDAQ:CTIC) was suspended earlier Tuesday pending the news, and
closed up $4.75 at $52 after trading resumed.
Company officials said the approval is one that could have far-reaching implications in oncology therapy
in this and other indications.
"I think it`s fair to say the FDA worked expeditiously and diligently," CTI CEO and President James Bianco
said. "They worked through the Fourth of July holiday and worked hard at getting us through the package
insertion issues and the audits within the deadline, and we`re very pleased with the outcome."
Bianco said the company has already put its sales force into place. Two directors, one on each coast,
will supervise the 16-person sales force, each of whom is called an oncology account manager.
"We currently have 16 oncology account managers in the field, and one East Coast and one West Coast
director," Bianco said. "We have the infrastructure in place and what we call demand creation ability.
Each of these account managers has about eight years experience, and their managers have about 10
years experience each, and they`re all out of companies like SmithKline Beecham, Aventis and Bristol
Myers Squibb Co., companies with known oncology experience, so we should be in a position to ship
drugs to our customers within the first week of October."
Bianco said the ability to market and distribute the drug independently should make it more profitable.
"The expectation at this time is that it`s an attractive commercial opportunity for the company," he said.
"We think we understand the oncology space well, and with our sales force in that market able to create
demand for the product we think we can accomplish a lot."
Bianco said the market for Trisenox is between 1,500 and 2,000 patients in the U.S. annually. He added
that Europe contains a similar market.
He said the company anticipates pricing the therapy from about $12,000 to $16,000 per patient annually.
At the high end, the company stands to gross about $32 million in the first year of commercialization.
He added that the company has plans for expansion into the European market, either through a
partnership, which the company is currently seeking, or independently.
"We`re actually preparing to file our marketing application [in Europe] in the fourth quarter of this year, so
the product approval may come as early as next year," he said.
CTI also plans to pursue a clinical study intended to expand Trisenox`s indication to include multiple
myeloma and lymphoma, among other blood cell and solid tumor cancers.
"There`s a fair amount of clinical data already indicating preliminary results in those indications," Bianco
said. "Our challenge is to put together a robust clinical program that pursues each of these indications
as extensions to the label indication."
www.BioWorld.com:
Cell Therapeutics Gets FDA Approval For Leukemia Drug
By Matthew Willett
Staff Writer
Published on September 27, 2000
Cell Therapeutics Inc. said its apoptosis-inducing leukemia therapeutic Trisenox (arsenic trioxide)
received FDA approval for treatment of acute promyelocytic leukemia.
The company plans to market the drug independently, using a 16-person sales force.
Trading in the company`s stock (NASDAQ:CTIC) was suspended earlier Tuesday pending the news, and
closed up $4.75 at $52 after trading resumed.
Company officials said the approval is one that could have far-reaching implications in oncology therapy
in this and other indications.
"I think it`s fair to say the FDA worked expeditiously and diligently," CTI CEO and President James Bianco
said. "They worked through the Fourth of July holiday and worked hard at getting us through the package
insertion issues and the audits within the deadline, and we`re very pleased with the outcome."
Bianco said the company has already put its sales force into place. Two directors, one on each coast,
will supervise the 16-person sales force, each of whom is called an oncology account manager.
"We currently have 16 oncology account managers in the field, and one East Coast and one West Coast
director," Bianco said. "We have the infrastructure in place and what we call demand creation ability.
Each of these account managers has about eight years experience, and their managers have about 10
years experience each, and they`re all out of companies like SmithKline Beecham, Aventis and Bristol
Myers Squibb Co., companies with known oncology experience, so we should be in a position to ship
drugs to our customers within the first week of October."
Bianco said the ability to market and distribute the drug independently should make it more profitable.
"The expectation at this time is that it`s an attractive commercial opportunity for the company," he said.
"We think we understand the oncology space well, and with our sales force in that market able to create
demand for the product we think we can accomplish a lot."
Bianco said the market for Trisenox is between 1,500 and 2,000 patients in the U.S. annually. He added
that Europe contains a similar market.
He said the company anticipates pricing the therapy from about $12,000 to $16,000 per patient annually.
At the high end, the company stands to gross about $32 million in the first year of commercialization.
He added that the company has plans for expansion into the European market, either through a
partnership, which the company is currently seeking, or independently.
"We`re actually preparing to file our marketing application [in Europe] in the fourth quarter of this year, so
the product approval may come as early as next year," he said.
CTI also plans to pursue a clinical study intended to expand Trisenox`s indication to include multiple
myeloma and lymphoma, among other blood cell and solid tumor cancers.
"There`s a fair amount of clinical data already indicating preliminary results in those indications," Bianco
said. "Our challenge is to put together a robust clinical program that pursues each of these indications
as extensions to the label indication."
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
228 | ||
175 | ||
62 | ||
56 | ||
55 | ||
49 | ||
45 | ||
44 | ||
33 | ||
31 |
Wertpapier | Beiträge | |
---|---|---|
28 | ||
25 | ||
23 | ||
19 | ||
19 | ||
19 | ||
19 | ||
18 | ||
18 | ||
17 |